News and Insights

FINN Partners named global Agency of Record for AD/PD™ Conference, advancing breakthroughs in neurodegenerative disease

September 14, 2026

Partnership leverages FINN specialized experience in brain health communications, supporting a shared mission to advance translational neuroscience worldwide

AD/PD™, a leading international conference dedicated to advancing science and treatment strategies in neurodegenerative diseases, has appointed FINN Partners as its global public relations agency of record (AOR).

FINN Partners will drive a global communications campaign to elevate visibility for AD/PD™, spotlighting its pivotal role as a hub for breakthrough research on Alzheimer’s disease, Parkinson’s disease, and related neurodegenerative disorders. The partnership comes ahead of the AD/PD™ 2027 conference, taking place 16 – 20 March 2027, in Barcelona, Spain, and online as a hybrid event.

“What sets AD/PD™ apart is our comprehensive focus across the spectrum of neurodegenerative diseases and our commitment to bringing together scientists, clinicians, and industry leaders to translate research into real-world care,” said Dr. Abraham Fisher, co-founder and president of AD/PD™. “As we prepare for AD/PD™ 2027 in Barcelona, partnering with FINN allows us to amplify our message, reach a broader global audience, and accelerate scientific collaboration that ultimately leads to life-changing diagnostics and therapies for patients worldwide.”

Leveraging the agency’s expertise in global health, neurology, and medical technology, the FINN Global Health Practice will lead media relations and stakeholder engagement to expand the conference’s footprint, strengthen participation among international clinical and scientific communities, and position AD/PD™ as an essential venue for translational neuroscience.

“Brain health is one of the most critical and rapidly evolving domains in medicine today, affecting millions of families worldwide,” said Richard Hatzfeld, senior partner and Brain Health Lead, FINN Partners. “AD/PD™ has long been the epicenter for scientific discovery in Alzheimer’s, Parkinson’s, and related conditions. We are honored to serve as their strategic PR partner, mobilizing our ‘One FINN’ collaborative model across our Health Practice to elevate AD/PD™’s mission and accelerate the impact of groundbreaking science on a global scale.”

FINN Partners’ selection highlights its position as a leading global health communications agency, operating across 38 offices and with specialized experience and capabilities in brain health and neurodegenerative science. FINN will support AD/PD™ in driving international abstract submissions and delegate participation, spotlighting innovative research across the conference’s 12 scientific tracks, and communicating key milestones and breakthrough discoveries leading up to and throughout the event.

“Many of our biotech, pharma, and health tech clients participated in and presented groundbreaking research at AD/PD™ through the years, making this partnership a natural extension of our work in the neurodegenerative space,” added Ellie Hanson, senior partner, co-lead of FINN Partners Israel. “We are thrilled to work alongside the AD/PD™ leadership team to elevate their international profile, increase delegate and speaker engagement, and champion the scientists and innovators working diligently to solve complex brain health challenges.”